Vertex's Next Steps Closely Watched Following Merck-Roche Deal On Victrelis
Executive Summary
All eyes are on Vertex Pharmaceuticals and whether it will change course and seek a marketing partner following the May 17 announcement that Merck and Roche will co-promote Merck’s newly approved hepatitis C drug Victrelis (boceprevir).
You may also be interested in...
Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo
Phase II ELECTRON study yielded 100% cure rate across all arms, including interferon-sparing and interferon-free regimens.
Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.
Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: